



EffeMarket



Global Gene Therapy Market Report -2026

July 2018

Table of Contents

- 1 Executive Summary**
- 2 Gene Therapy: Overview**
 - Viral Vectors for Gene Therapy**
 - Viral Vectors
 - Non-Viral Vectors
 - Types of Gene Therapy**
 - Somatic Gene Therapy
 - Germ Line Gene Therapy
 - Approaches to Gene Therapy**
 - Gene Therapy Strategies
 - Gene Augmentation Therapy
 - Targeted Killing of Specific Cells
 - Targeted Inhibition of Gene Expression
 - Targeted Gene Mutation Correction
 - Gene Therapy Methods**
 - Ex Vivo Gene Therapy
 - In Vivo Gene Therapy
 - Advantages and Disadvantages of Gene Therapy**
 - Advantages
 - Disadvantages
 - Major Applications of Gene Therapy**
- 3 Gene Therapy Market Outlook and Forecast**
 - Global Gene Therapy Market: An Analysis
 - Global Gene Therapy Market by Value
 - Global Gene Therapy Market by Therapy Area
 - Global Gene Therapy Market by Vector type
 - Global Gene Therapy Market by Clinical Trials
 - Global Gene Therapy Market by Regions
 - US Gene Therapy Market: An Analysis**
 - US Gene Therapy Market by Therapy Area
 - Europe Gene Therapy Market: An Analysis**
 - Asia Gene Therapy Market**
- 4 Patent Landscape**
 - Gene Therapy Patent Trend by Focus Area
 - Gene Therapy Patent Trend by Gene Transfer Method
 - Gene Therapy Patent Trend by Therapy Techniques
 - Gene Therapy Patent Trend by Applications
 - Key Patents in the domain
 - Gene Therapy Patents by Key Players
 - Gene Therapy Patents by Key Inventors

5 Market Dynamics

Growth Drivers

- Failure of Conventional Therapies to Treat Cancer
- Enhance Gene Therapy Awareness Among Developed Nations
- Approvals of Gene Therapy Drug in Europe
- Gene Therapy for Hemophilia B and Inherited Blindness

Trends

- Gene Silencing
- Combining Stem Cell Technology & Gene Therapy
- Empowering Gene therapy: Nanotechnology
- Stringent Laws and Safety Concerns

Challenges in Commercialization of Gene Therapy

- High Cost of Gene Therapy Drugs
- Pitfall in Current Technologies

6 Mergers and Acquisitions

7 Competitive Landscape

8 Company Profiles

Pfizer

- Business Overview
- Financial Overview
- Product Overview

Celgene

- Business Overview
- Financial Overview
- Product Overview

Spark Therapeutics

- Business Overview
- Financial Overview
- Product Overview

GlaxoSmithKline

- Business Overview
- Financial Overview
- Product Overview

Blubirdbio Therapeutics

- Business Overview
- Financial Overview
- Product Overview

Sanofi

- Business Overview
- Financial Overview
- Product Overview

Unique

Business Overview

Product Overview

Orchard Therapeutics

Business Overview

Financial Overview

Product Overview

Abeona Therapeutics

Business Therapeutics

Financial Overview

Product Overview

Oxford Biomedica

Business Overview

Financial Overview

Product Overview

9 About EffeMarket

10 Disclaimer

11 Contact US

List of Figures

- Figure 1: Genetic Makeup of an Organism
- Figure 2: General DNA Cloning using Vector System
- Figure 3: Vectors Used in Gene Therapy
- Figure 4: Adenoviral Vector: Mechanism of action
- Figure 5: Retroviral Vector: Mechanism of Action
- Figure 6: Direct Injection/Microinjection
- Figure 7: Particle Bombardment Method of Gene Transfer
- Figure 8: Liposome Mediated Gene Transfer
- Figure 9: Electroporation Method of Gene Transfer
- Figure 10: Different Classes of Gene Therapy
- Figure 11: Gene Therapy Approaches
- Figure 12: Different Strategies of Gene Therapy
- Figure 13: Gene Augmentation Therapy
- Figure 14: Targeted Killing of Specific Cells
- Figure 15: Targeted inhibition of Gene Expression
- Figure 16: Targeted Gene Mutation Correction
- Figure 17: Gene Therapy Methods
- Figure 18: Ex Vivo Gene Therapy
- Figure 19: In Vivo Gene Therapy
- Figure 20: Global Gene Therapy Market by Value; 2014-2026
- Figure 21: Global Gene Therapy Market Share by Therapy Area; 2015
- Figure 22: Global Gene Therapy Market Share by Vector Type; 2015
- Figure 23: Global Gene Therapy Market Share by Vector Type; 2015
- Figure 24: Global Gene Therapy Clinical Trials by Therapy Areas; 2017
- Figure 25: Global Gene Therapy Market Share by Regions; 2018
- Figure 26: Global Gene Therapy Market by M&A Deals; 2017
- Figure 27: US Gene Therapy Market by Value; 2013-2026
- Figure 28: US Hematology Gene Therapy Market by Value; 2013-2026
- Figure 29: US Oncology Gene Therapy Market by Value; 2013-2026
- Figure 30: US Infectious disease Gene Therapy Market by Value; 2013-2026
- Figure 31: US Muscular Disease Gene Therapy Market by Value; 2013-2026
- Figure 32: Europe Gene Therapy Market by Value; 2014-2026
- Figure 33: Europe Gene Therapy Market Share by Sector; 2014-2026
- Figure 34: Europe Gene Therapy Market by Companies; 2014-2026
- Figure 35: Europe Gene Therapy Market by Academic and Government Research Institutions; 2014-2026
- Figure 36: Europe Gene Therapy Market by Contract and Research Institutions; 2014-2026
- Figure 37: Asia Gene Therapy Market by Value; 2014-2026
- Figure 38: Australasia Gene Therapy Market by Value; 2014-2026
- Figure 39: Overall IP Trends in Gene Therapy; 1988-2018

- Figure 40: Earliest Priority Country Filing Trend in Gene Therapy; 1988-2018
- Figure 41: Gene Therapy Patent Trend by Focus Area; 1988-2018
- Figure 42: Gene Therapy Patent Trend by Focus Area; 1988-2018
- Figure 43: Gene Therapy Patent Trend by Viral & Non-Viral Vector; 1988-2018
- Figure 44: Gene Therapy Patent Trend by Viral Vector; 1988-2018
- Figure 45: Gene Therapy Patent Trend by Non-Viral Vector; 1988-2018
- Figure 46: Gene Therapy Patent Trend by Therapy Techniques; 1988-2018
- Figure 47: Gene Therapy Patent Trend by Therapy Techniques; 1988-2018
- Figure 48: Gene Therapy Patent Trend by Key Patent Holders (Legal Assignees); 1988-2018
- Figure 49: Gene Therapy Patent Trend by Top Inventors in the domain
- Figure 50: CAR-T Cell Therapy
- Figure 51: Number of Patent Applications in China
- Figure 52: Total Patent Applications; 2017
- Figure 53: Types of Gene Silencing
- Figure 54: Gene Silencing Mechanism
- Figure 55: Research Papers and Citations in Gene Silencing Area; 2002-2003
- Figure 56: Principles for the Governance of Gene Editing
- Figure 57: Number of Approved Gene Therapy Trials Worldwide; 1989-2015
- Figure 58: Prices of Gene Therapy Products
- Figure 59: Pfizer Revenue; 2013-2017
- Figure 60: Celgene Revenue; 2013-2017
- Figure 61: Celgene R&D Expenses; 2015-2017
- Figure 62: Spark Therapeutics Revenue; 2013-2017
- Figure 63: Spark Therapeutics R&D Expenses; 2013-2017
- Figure 64: GlaxoSmithKline Revenue; 2015-2017
- Figure 65: GlaxoSmithKline R&D Expenses; 2015-2017
- Figure 66: Blubirdbio Revenue; 2013-2017
- Figure 67: Blubirdbio R&D Expenses ;2013-2017
- Figure 68: Sanofi Revenue; 2013-2017
- Figure 69: Uniqure Revenue; 2013-2017
- Figure 70: Uniqure R&D Expenses;2013-2017
- Figure 71: Orchard Therapeutics Total Capital Raised
- Figure 72: Abeona Revenue; 2013-2017
- Figure 73: Abeona R&D Expenses; 2013-2017
- Figure 74: Oxford Biomedica Revenue; 2013-2017
- Figure 75: Oxford BiomedicaR&D Expenses; 2013-2017

List of Tables

- Table 1: Viral and Non-Viral Gene Transfer Methods
- Table 3: Gene Therapy Products Approved by European Medicine Agency
- Table 4: Gene Therapy Patent Trend by Focus Area (Year Wise Filing); 2007-2018
- Table 5: Gene Therapy Patent Trend by Gene Transfer Method (Year Wise Filing); 2007-2018
- Table 6: Gene Therapy Patent Trend by Applications; 2007-2018
- Table 7: Key Patents in the domain
- Table 8: Key Players Year Wise Patent Publication;2007-2018
- Table 9: Key Players Year role in patent focus
- Table 10: Key Players Year role in Gene transfer Method
- Table 11: Key Players role in Applications
- Table 12: Key Players Collaboration
- Table 13: Top Inventors actively associated with the key players
- Table 14: Top Inventors Gene Therapy for Hemophilia B
- Table 15: Competitive Landscape
- Table 16: Major Pharma Collaborations for Gene Strategy Implementation
- Table 17: Spark Therapeutics Product Pipeline
- Table 18: Blubirdbio Therapeutics Product Pipeline
- Table 19: Sanofi Product Pipeline
- Table 20: Uniqure Product Pipeline
- Table 21: Orchard Therapeutics Product Pipeline
- Table 22: Abeona Therapeutics Product Pipeline
- Table 23: Oxford Biomedica Product Pipeline

Executive Summary

Gene therapy is an experimental technique that encompasses the replacement of mutated genes with healthy genes. Gene therapy is considered to be an effective treatment for chronic diseases as they cause minimum side effects with maximum efficacy and may help in an eradication of disease at a root cause level.

It's an experimental technique that uses genes from another source to treat or prevent any type of genetic disorder. The rise in prevalence of cancer, benefits of cancer gene therapy over conventional cancer therapies, rising awareness among developing nations, approval of gene therapy products in developed nations like Europe and the advancement in this field are the major factors that are driving the market growth.

The growing popularity of the gene therapy market can be correlated with increasing number of clinical trials due to rising incidence of various types of skin disease, rise in funding for R&D activities, increase in awareness, and investment from government bodies. Over the year's ethical acceptance of gene therapy especially with respect to the cancer treatment has grown which is further fueling the growth of gene therapy market. Moreover, rise in biotechnological funding, initiatives taken by government bodies to encourage R&D activities are also other factors driving the gene therapy market. However high costs associated with the treatment, unwanted immune response, pitfall in current technologies, stringent laws and safety and challenges in commercialization of gene therapy market are restraining the market growth.

The overall global gene therapy market is expected to witness a significant growth as it may reach approximately US\$2543 million by the end of the year 2026. Several bioengineers, professionals are focusing to develop and support gene therapies with improved efficacy and safety and are aiming more towards advanced platforms for the engineering of vectors. It has also led to discovery of many novel molecular targets which has further enhanced and strengthened the research and product pipeline. Hence, the diverse product pipeline is driving factor for the growth of gene therapy market. The overall gene therapy market is segmented based on therapy area where cancer is dominating the market. Based on geographic area US is holding the major market share among Europe, Asia, Australasia.

The various key players that are playing the lead role in the gene therapy market are Pfizer, Celgene, Spark Therapeutics, GlaxoSmithKline, Bluebird bio Therapeutics, Sanofi, Uniqure, Orchard Therapeutics, Abeona Therapeutics, Oxford Biomedica. Glybera, the first gene therapy product which is used for the treatment of lipoprotein lipase deficiency is the product of Uniqure and has been given an orphan drug status in the European Union as well as the US. Strimvelis,

another gene therapy product developed by GlaxoSmithKline which proved to be successful against ADA-SCID (Severe Combined Immune Deficiency). SPK9001 is another breakthrough product against Hemophilia B was developed by Spark and Pfizer, which involves a bioengineered gene designed to prompt the body to produce increased levels of a different clotting factors. The report provides an extensive study on the current market landscape of gene therapies by therapy area, by regions, by vectors and by key players, featuring an elaborate discussion on the future potential of this evolving market.

Key Questions Answered

1. Global Gene Therapy Market by Value; 2014-2026
2. Global Gene Therapy Market Share by Therapy Area; 2015
3. Global Gene Therapy Market Share by Vectors; 2015
4. Global Gene Therapy Clinical Trials by Therapy Areas; 2017
5. Global Gene Therapy Market Share by Regions; 2018
6. Global Gene Therapy Market by M&A Deals; 2017
7. US Gene Therapy Market by Value; 2013-2026
8. US Gene Therapy Share by Therapy Area; 2013-2026
9. US Hematology Gene Therapy Market by Value; 2013-2026
10. US Oncology Gene Therapy Market by Value; 2013-2026
11. US Infectious disease Gene Therapy Market by Value; 2013-2026
12. US Muscular Disease Gene Therapy Market by Value; 2013-2026
13. Europe Gene Therapy Market by Value; 2014-2026
14. Europe Gene Therapy Market Share by Sector; 2014-2026
15. Europe Gene Therapy Market by Companies; 2014-2026
16. Europe Gene Therapy Market by Academic and Government Research Institutions; 2014-2026
17. Europe Gene Therapy Market by Contract and Research Institutions; 2014-2026
18. Asia Gene Therapy Market by Value; 2014-2026
19. Australasia Gene Therapy Market by Value; 2014-2026
20. Number of Approved Gene Therapy Trials Worldwide; 1989-2015
21. Patent Landscape
22. Growth drivers, future opportunities and challenges in the market
23. Merger and Acquisition, and Collaboration of Key Players
24. Detailed company profiling of key market players

About EffeMarket

EffeMarket provides market and business research solutions to clients in over 20 industries through syndicated studies, custom research, consulting engagements and newsletters. Our experienced analyst and widespread network of experts ensures accuracy within studies and provides our patrons with extensively researched, fact-based insights that help you to take better decisions.

Disclaimer

EffeMarket reports and their contents, including all the analysis and research containing valuable market information, are provided to a select group of customers in response to orders. Our customers acknowledge when ordering that EffeMarket reports including all research and insights in their entirety are for our customers' internal use and not for general publication or disclosure to third parties. The market information is based primarily on secondary research and interviews and therefore, is subject to changes. EffeMarket takes no responsibility for any incorrect information supplied to us through such sources.

Contact US

For any questions and updates, please contact:

Sales@effemarket.com

Support@effemarket.com

Website: www.effemarket.com

Phone:

US: +1-972-256-8133

UK: +44-203-286-8233

IN: +91 120 4561797

Address: Effectual Knowledge Services Pvt. Ltd. B-55, Sector 2, Noida – 201301, U.P., India

US Office – New York

Effectual Knowledge Services, Inc. 425 Broadhollow Road, Suite 427, Melville | NY 11747